Study of the mutations in the HCV genome and human genetic variations
Project/Area Number |
15K09004
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | Hiroshima University |
Principal Investigator |
Ochi Hidenori 広島大学, 医歯薬保健学研究科(医), 講師 (10415119)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | HCV / ウイルス変異 / 直接作用型抗ウイルス薬 / 薬剤耐性変異 / ヒトゲノム多様性 / ゲノムワイド関連解析 / 遺伝子多型 |
Outline of Final Research Achievements |
A system to rapidly and accurately evaluate the proportion of HCV mutant strains was developed, which enabled us to further study the efficacy of various direct acting drugs regimens and their relationships with resistant associated variants (RAVs). NS5A-Y93H substitution at baseline could be frequently found and thus regarded as naturally occurring RAV. It was associated with viral titer, the number of mutations within the NS5A-ISDR, ALT levels, and IL28B variant. Association of NS5B-C316N and core 70 amino acid substitutions with human genetic variants were examined and found that there were some associations between viral mutations and human polymorphisms. These findings may provide new insights into an understanding of viral escape from the host immune system and the viral molecular evolution as well as the virological mechanisms of HCV drug resistance.
|
Report
(4 results)
Research Products
(12 results)
-
-
-
-
[Journal Article] Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.2017
Author(s)
Morio K, Imamura M, Kawakami Y, Morio R, Kobayashi T, Yokoyama S, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Makokha GN, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K, Chayama K.
-
Journal Title
J Gastroenterol Hepatol.
Volume: 32
Issue: 3
Pages: 645-650
DOI
Related Report
Peer Reviewed
-
[Journal Article] Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.2017
Author(s)
Morio R, Imamura M, Kawakami Y, Morio K, Kobayashi T, Yokoyama S, Kimura Y, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Nelson Hayes C, Aikata H, Takahashi S, Miki D, Ochi H, Mori N, Takaki S, Tsuji K, Chayama K.
-
Journal Title
J Gastroenterol.
Volume: 52
Issue: 4
Pages: 504-511
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.2017
Author(s)
Nakamura Y, Imamura M, Kawakami Y, Teraoka Y, Daijo K, Honda F, Morio K, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Miki D, Ochi H, Chayama K.
-
Journal Title
J Med Virol.
Volume: 89
Issue: 4
Pages: 665-671
DOI
Related Report
Peer Reviewed
-
[Journal Article] Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing2016
Author(s)
Kan H, Imamura M, Uchida T, Hiraga N, Hayes CN, Tsuge M, Abe H, Aikata H, Makokha GN, Chowdhury S, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.
-
Journal Title
Journal of Infectious Disease
Volume: 214
Issue: 11
Pages: 1687-1694
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay2015
Author(s)
Satoshi Yoshimi, Hidenori Ochi, Eisuke Murakami, Takuro Uchida, Hiromi Kan, Sakura Akamatsu, C. Nelson Hayes, Hiromi Abe, Daiki Miki, Nobuhiko Hiraga, Michio Imamura, Hiroshi Aikata, Kazuaki Chayama.
-
Journal Title
PLOS ONE
Volume: 10
Issue: 6
Pages: e0130022-e0130022
DOI
Related Report
Peer Reviewed / Open Access
-
[Presentation] Protease inhibitor resistance remains even after mutant strains become undetectable using ultra-deep sequencing.2016
Author(s)
Kan H, Imamura M, Hiraga N, Hayes CN, Uchida T, Miyaki E, Tsuge M, Abe-Chayama H, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.
Organizer
67th AASLD
Place of Presentation
Boston MA, USA
Year and Date
2016-11-11
Related Report
Int'l Joint Research
-
[Presentation] 代償性肝硬変患者に対するDaclatasvir/Asunaprevir併用療法の有効性および安全性の検討2016
Author(s)
盛生慶, 今村道雄, 川上由育, 中村有希, 本田芙美, 小林知樹, 長沖祐子, 河岡友和, 柘植雅貴, 平松憲, 相方浩, 越智秀典, 茶山一彰,森奈美, 高木慎太郎, 辻恵二
Organizer
第20回日本肝臓学会総会
Place of Presentation
神戸
Year and Date
2016-11-03
Related Report
-
[Presentation] 腎機能障害を有するC型慢性肝炎におけるダクラタスビル・アスナプレビル療法の有効性と安全性の検討2016
Author(s)
中村有希, 今村道雄, 川上由育, 盛生慶, 盛生玲央奈, 本田芙美, 小林知樹, 中原隆志, 長沖祐子, 河岡友和, 柘植雅貴, 平松憲, 相方浩, 越智秀典, 茶山一彰, 森奈美, 高木慎太郎, 辻恵二
Organizer
第20回日本肝臓学会総会
Place of Presentation
神戸
Year and Date
2016-11-03
Related Report
-
[Presentation] Rapid, sensitive, and accurate evaluation system for drug resistant strain (NS5A-Y93H) frequency in genotype 1b HCV2015
Author(s)
Hidenori Ochi, Satoshi Yoshimi, Eisuke Murakami, Takuro Uchida, Hiromi Kan, Sakura Akamatsu, C. Nelson Hayes, Hiromi Abe, Daiki Miki, Nobuhiko Hiraga, Michio Imamura, Hiroshi Aikata, Kazuaki Chayama.
Organizer
AASLD Liver Meeting 2015
Place of Presentation
San Francisco (United States)
Year and Date
2015-11-13
Related Report
Int'l Joint Research